$MYO
MYOMO, INC.

2024 Q3 Form 10-Q Financial Statement

#000095017024091839 Filed on August 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $9.208M $7.521M $5.959M
YoY Change 81.27% 26.22% 62.02%
Cost Of Revenue $2.262M $2.195M $1.677M
YoY Change 42.21% 30.87% 32.4%
Gross Profit $6.946M $5.326M $4.281M
YoY Change 99.08% 24.4% 77.59%
Gross Profit Margin 75.43% 70.81% 71.85%
Selling, General & Admin $6.654M $5.433M $4.820M
YoY Change 38.75% 12.73% 3.34%
% of Gross Profit 95.81% 102.02% 112.59%
Research & Development $1.249M $1.007M $564.2K
YoY Change 74.12% 78.51% -10.85%
% of Gross Profit 17.98% 18.91% 13.18%
Depreciation & Amortization $48.69K $35.97K $51.99K
YoY Change 36.01% -30.81% 6.06%
% of Gross Profit 0.7% 0.68% 1.21%
Operating Expenses $7.903M $6.441M $5.384M
YoY Change 43.35% 19.62% 1.64%
Operating Profit -$957.6K -$1.115M -$1.103M
YoY Change -52.7% 1.09% -61.79%
Interest Expense $76.02K $107.2K $103.4K
YoY Change -32.31% 3.68% 2378.17%
% of Operating Profit
Other Income/Expense, Net $76.02K $107.2K $85.29K
YoY Change 82.26% 25.73% -393.77%
Pretax Income -$881.5K -$1.008M -$1.018M
YoY Change -55.54% -0.97% -65.09%
Income Tax $84.88K $113.8K -$3.562K
% Of Pretax Income
Net Earnings -$966.4K -$1.122M -$1.014M
YoY Change -52.37% 10.6% -65.14%
Net Earnings / Revenue -10.5% -14.91% -17.02%
Basic Earnings Per Share -$0.03 -$0.03 -$0.04
Diluted Earnings Per Share -$0.03 -$0.03 -$0.04
COMMON SHARES
Basic Shares Outstanding 30.23M 28.81M 20.92M
Diluted Shares Outstanding 37.95M 37.37M 27.99M

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.957M
YoY Change -12.5%
Cash & Equivalents $6.623M $5.846M $6.006M
Short-Term Investments $2.950M
Other Short-Term Assets $694.6K
YoY Change 53.99%
Inventory $3.384M $2.601M $1.337M
Prepaid Expenses
Receivables $3.729M $2.526M $1.642M
Other Receivables $0.00
Total Short-Term Assets $14.70M $15.14M $12.63M
YoY Change -8.34% 19.88% -5.07%
LONG-TERM ASSETS
Property, Plant & Equipment $561.3K $289.3K $153.7K
YoY Change 226.32% 88.2% -45.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $102.8K
YoY Change -38.01%
Other Assets $205.4K $219.9K $111.0K
YoY Change 125.17% 98.04% 0.0%
Total Long-Term Assets $1.609M $1.049M $666.6K
YoY Change 59.0% 57.31% -46.93%
TOTAL ASSETS
Total Short-Term Assets $14.70M $15.14M $12.63M
Total Long-Term Assets $1.609M $1.049M $666.6K
Total Assets $16.31M $16.19M $13.30M
YoY Change -4.35% 21.76% -8.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $766.6K
YoY Change -10.82%
Accrued Expenses $3.393M
YoY Change 12.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.991M $6.465M $4.337M
YoY Change 21.01% 49.07% 11.66%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $139.8K
YoY Change -57.6%
Total Long-Term Liabilities $139.8K
YoY Change -57.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.991M $6.465M $4.337M
Total Long-Term Liabilities $139.8K
Total Liabilities $7.021M $6.513M $4.477M
YoY Change 16.41% 45.47% 6.24%
SHAREHOLDERS EQUITY
Retained Earnings -$102.9M -$101.9M -$92.44M
YoY Change 8.87% 10.22% 10.31%
Common Stock $111.8M $111.4M $101.2M
YoY Change 5.92% 10.08% 7.52%
Preferred Stock
YoY Change
Treasury Stock (at cost) $6.464K $6.464K $6.464K
YoY Change 0.0% 0.0% 0.0%
Treasury Stock Shares
Shareholders Equity $9.292M $9.678M $8.820M
YoY Change
Total Liabilities & Shareholders Equity $16.31M $16.19M $13.30M
YoY Change -4.35% 21.76% -8.68%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$966.4K -$1.122M -$1.014M
YoY Change -52.37% 10.6% -65.14%
Depreciation, Depletion And Amortization $48.69K $35.97K $51.99K
YoY Change 36.01% -30.81% 6.06%
Cash From Operating Activities -$1.494M -$1.916M -$285.5K
YoY Change -12.87% 571.03% -89.22%
INVESTING ACTIVITIES
Capital Expenditures $320.7K $119.4K $14.97K
YoY Change 492.92% 697.33% -128.36%
Acquisitions
YoY Change
Other Investing Activities $3.146M $2.450M -$2.949M
YoY Change -349.42% -183.09%
Cash From Investing Activities $2.825M $2.331M -$2.964M
YoY Change -314.78% -178.64% 5513.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -199.5K 0.000 -8.150K
YoY Change -105.05% -100.0%
NET CHANGE
Cash From Operating Activities -1.494M -1.916M -285.5K
Cash From Investing Activities 2.825M 2.331M -2.964M
Cash From Financing Activities -199.5K 0.000 -8.150K
Net Change In Cash 1.131M 414.7K -3.257M
YoY Change 23.07% -112.73% 20.6%
FREE CASH FLOW
Cash From Operating Activities -$1.494M -$1.916M -$285.5K
Capital Expenditures $320.7K $119.4K $14.97K
Free Cash Flow -$1.815M -$2.035M -$300.5K
YoY Change 2.6% 577.32% -88.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001369290
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38109
dei Entity Registrant Name
EntityRegistrantName
MYOMO, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-0944526
dei Entity Address Address Line1
EntityAddressAddressLine1
137 Portland St.
dei Entity Address Address Line2
EntityAddressAddressLine2
4th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02114
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
996-9058
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
MYO
dei Security Exchange Name
SecurityExchangeName
NYSEAMER
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30225752
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5846100
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6871306
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
3135801
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
1994662
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2526361
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2382658
CY2024Q2 us-gaap Inventory Net
InventoryNet
2601104
CY2023Q4 us-gaap Inventory Net
InventoryNet
1803507
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1032323
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
598850
CY2024Q2 us-gaap Assets Current
AssetsCurrent
15141689
CY2023Q4 us-gaap Assets Current
AssetsCurrent
13650983
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
539498
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
663554
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
289303
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
175794
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
219891
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
91237
CY2024Q2 us-gaap Assets
Assets
16190381
CY2023Q4 us-gaap Assets
Assets
14581568
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5868407
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4885944
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
316600
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
486143
CY2024Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
268310
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
96461
CY2024Q2 us-gaap Deferred Income Current
DeferredIncomeCurrent
12015
CY2023Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
8510
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6465332
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5477058
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
47338
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
115160
CY2024Q2 us-gaap Liabilities
Liabilities
6512670
CY2023Q4 us-gaap Liabilities
Liabilities
5592218
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30201354
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27135061
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30201327
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27135034
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
3021
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2715
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
111430314
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
105840239
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
138888
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
83669
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101888048
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-96930809
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
27
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
27
CY2024Q2 us-gaap Treasury Stock Value
TreasuryStockValue
6464
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
6464
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
9677711
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
8989350
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16190381
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14581568
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7520767
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5958544
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11275156
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9405252
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
2195255
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
1677488
us-gaap Cost Of Revenue
CostOfRevenue
3650601
us-gaap Cost Of Revenue
CostOfRevenue
2816594
CY2024Q2 us-gaap Gross Profit
GrossProfit
5325512
CY2023Q2 us-gaap Gross Profit
GrossProfit
4281056
us-gaap Gross Profit
GrossProfit
7624555
us-gaap Gross Profit
GrossProfit
6588658
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1007224
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
564235
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1963438
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1041225
CY2024Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2777135
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2271937
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5138980
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4302488
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2656217
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2547890
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5525968
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5018947
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
6440576
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
5384062
us-gaap Operating Expenses
OperatingExpenses
12628386
us-gaap Operating Expenses
OperatingExpenses
10362660
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1115064
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1103006
us-gaap Operating Income Loss
OperatingIncomeLoss
-5003831
us-gaap Operating Income Loss
OperatingIncomeLoss
-3774002
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
107242
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
103439
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
242535
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
189753
CY2024Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0
CY2023Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
5631
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
5631
CY2024Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
12514
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
29716
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
107242
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
85294
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
242535
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
154406
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1007822
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1017712
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4761296
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3619596
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
113785
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3562
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
195943
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
38849
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1121607
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1014150
us-gaap Net Income Loss
NetIncomeLoss
-4957239
us-gaap Net Income Loss
NetIncomeLoss
-3658445
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37368488
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37368488
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27992928
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27992928
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37060543
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37060543
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26000216
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26000216
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1121607
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1014150
us-gaap Net Income Loss
NetIncomeLoss
-4957239
us-gaap Net Income Loss
NetIncomeLoss
-3658445
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-9241
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-71357
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
52410
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5569
CY2024Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
618
CY2023Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
1634
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
2809
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
1634
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-8623
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-69723
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
55219
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3935
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1130230
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1083873
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4902020
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3662380
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
8989350
CY2024Q1 myo Proceeds From Sale Of Common Stock In Public Offering Net Of Offering Costs Value
ProceedsFromSaleOfCommonStockInPublicOfferingNetOfOfferingCostsValue
4598771
CY2024Q1 myo Proceeds From Sale Of Pre Funded Warrants Net Of Offering Costs
ProceedsFromSaleOfPreFundedWarrantsNetOfOfferingCosts
763138
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
320288
CY2024Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
63842
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3835632
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
10899757
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
10899757
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-91893
CY2024Q2 myo Common Stock Issued For Warrants Exercised
CommonStockIssuedForWarrantsExercised
77
CY2024Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-8623
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1121607
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
9677711
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
6359365
CY2023Q1 myo Proceeds From Sale Of Common Stock In Public Offering Net Of Offering Costs Value
ProceedsFromSaleOfCommonStockInPublicOfferingNetOfOfferingCostsValue
3616094
CY2023Q1 myo Proceeds From Sale Of Pre Funded Warrants Net Of Offering Costs
ProceedsFromSaleOfPreFundedWarrantsNetOfOfferingCosts
2064012
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
171027
CY2023Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
65788
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2644295
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
9631991
CY2023Q2 myo Common Stock Issued Upon Vesting Of Restricted Stock Units
CommonStockIssuedUponVestingOfRestrictedStockUnits
16744
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-8147
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
280061
CY2023Q2 us-gaap Unrealized Gain Loss On Foreign Currency Derivatives Net Before Tax
UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
-71357
CY2023Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
1634
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1014150
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
8820032
us-gaap Profit Loss
ProfitLoss
-4957239
us-gaap Profit Loss
ProfitLoss
-3658445
us-gaap Depreciation
Depreciation
65663
us-gaap Depreciation
Depreciation
100622
us-gaap Share Based Compensation
ShareBasedCompensation
228395
us-gaap Share Based Compensation
ShareBasedCompensation
451088
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
108999
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
5257
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
13000
us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
0
us-gaap Debt And Equity Securities Realized Gain Loss
DebtAndEquitySecuritiesRealizedGainLoss
-29716
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
124057
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
209625
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-44631
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
10786
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
102234
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-235877
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
816055
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-68907
myo Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
363375
myo Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
212438
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
214937
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
990973
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
888594
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
176235
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
34774
myo Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-237365
myo Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-232467
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
3505
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-20280
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5161488
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2102213
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
5482757
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
3198634
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
4450000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
250000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
179173
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
60058
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1211930
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3008692
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4598771
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3708045
us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
0
us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-8147
myo Proceeds From At The Market Offering Net Of Offering Costs
ProceedsFromAtTheMarketOfferingNetOfOfferingCosts
763138
myo Proceeds From At The Market Offering Net Of Offering Costs
ProceedsFromAtTheMarketOfferingNetOfOfferingCosts
2064012
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5361909
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5763910
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-13697
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7311
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1025206
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
660316
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6871306
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5345967
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5846100
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6006283
myo Deferred Offering Costs Incurred In A Prior Period To Additional Paid In Capital
DeferredOfferingCostsIncurredInAPriorPeriodToAdditionalPaidInCapital
0
myo Deferred Offering Costs Incurred In A Prior Period To Additional Paid In Capital
DeferredOfferingCostsIncurredInAPriorPeriodToAdditionalPaidInCapital
-91952
myo Unrealized Loss From Mark To Market On Short Term Investments
UnrealizedLossFromMarkToMarketOnShortTermInvestments
2809
myo Unrealized Loss From Mark To Market On Short Term Investments
UnrealizedLossFromMarkToMarketOnShortTermInvestments
1634
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 1 — Description of Business</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Myomo Inc. (“Myomo” or the Company”) is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro ® myoelectric upper limb orthosis product is registered with the U.S. Food and Drug Administration as a Class II medical device. The Company sells its products directly to patients, to Orthotics and Prosthetics ("O&amp;P") providers around the world, the Veterans Health Administration, and distributors in Europe and Australia.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company was incorporated in the State of Delaware on September 1, 2004 and is headquartered in Boston, Massachusetts.</span></p>
myo Net Loss Income
NetLossIncome
4957200
myo Net Loss Income
NetLossIncome
3658400
CY2024Q2 myo Accumulated Deficit
AccumulatedDeficit
101888000
CY2023Q4 myo Accumulated Deficit
AccumulatedDeficit
96930800
myo Net Cash Provided By Used In Operating Activity
NetCashProvidedByUsedInOperatingActivity
5161500
myo Net Cash Provided By Used In Operating Activity
NetCashProvidedByUsedInOperatingActivity
2102200
CY2024Q3 us-gaap Debt Default Longterm Debt Amount
DebtDefaultLongtermDebtAmount
4000000
CY2024Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1354218
CY2024Q1 myo Salesofprefundedwarrants
Salesofprefundedwarrants
224730
CY2024Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
3.8
CY2024Q1 myo Per Sale Price Of Warrants
PerSalePriceOfWarrants
3.7999
CY2024Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
5400000
CY2023Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
5413334
CY2023Q3 myo Salesofprefundedwarrants
Salesofprefundedwarrants
1920000
CY2023Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.6
CY2023Q3 myo Per Sale Price Of Warrants
PerSalePriceOfWarrants
0.5999
CY2023Q3 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
3900000
CY2023Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
13169074
CY2023Q1 myo Salesofprefundedwarrants
Salesofprefundedwarrants
6830926
CY2023Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.325
CY2023Q1 myo Per Sale Price Of Warrants
PerSalePriceOfWarrants
0.3249
CY2023Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
5700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America require management to make estimates and assumptions that affect certain reported amounts and disclosures. These estimates and assumptions are reviewed on an on-going basis and updated as appropriate. Actual results could differ from these estimates. The Company’s significant estimates include deferred tax valuation allowances, valuation of stock-based compensation, warranty obligations and reserves for slow-moving inventory.</span></p>
CY2024Q2 us-gaap Other Short Term Investments
OtherShortTermInvestments
3135800
CY2023Q4 us-gaap Other Short Term Investments
OtherShortTermInvestments
1994700
CY2024Q2 myo Percentage Of Direct Billing Channel Revenue Insures Represent
PercentageOfDirectBillingChannelRevenueInsuresRepresent
0.27
CY2023Q2 myo Percentage Of Direct Billing Channel Revenue Insures Represent
PercentageOfDirectBillingChannelRevenueInsuresRepresent
0.53
myo Percentage Of Direct Billing Channel Revenue Insures Represent
PercentageOfDirectBillingChannelRevenueInsuresRepresent
0.35
myo Percentage Of Direct Billing Channel Revenue Insures Represent
PercentageOfDirectBillingChannelRevenueInsuresRepresent
0.57
CY2024Q2 us-gaap Deferred Revenue
DeferredRevenue
12000
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
8500
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7520767
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5958544
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11275156
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9405252
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
121800
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
144600
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
265600
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
366800
CY2024Q2 us-gaap Advertising Expense
AdvertisingExpense
849600
CY2023Q2 us-gaap Advertising Expense
AdvertisingExpense
846400
us-gaap Advertising Expense
AdvertisingExpense
1636900
us-gaap Advertising Expense
AdvertisingExpense
1537900
CY2024Q2 us-gaap Restructuring Reserve Translation Adjustment
RestructuringReserveTranslationAdjustment
9200
CY2023Q2 us-gaap Restructuring Reserve Translation Adjustment
RestructuringReserveTranslationAdjustment
71400
us-gaap Restructuring Reserve Translation Adjustment
RestructuringReserveTranslationAdjustment
52400
us-gaap Restructuring Reserve Translation Adjustment
RestructuringReserveTranslationAdjustment
5600
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1967741
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2303003
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0001
CY2024Q2 myo Common Stock Equivalents Pre Funded Warrants
CommonStockEquivalentsPreFundedWarrants
7721519
CY2023Q2 myo Common Stock Equivalents Pre Funded Warrants
CommonStockEquivalentsPreFundedWarrants
6830926
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
800305
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
321484
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
146945
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
6589
CY2024Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1653854
CY2023Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1475434
CY2024Q2 us-gaap Inventory Net
InventoryNet
2601104
CY2023Q4 us-gaap Inventory Net
InventoryNet
1803507
CY2024Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
4754628
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
3135801
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
1994662
CY2024Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1369978
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1073405
CY2024Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2174382
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1964487
CY2024Q2 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
349909
CY2023Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
95680
CY2024Q2 myo Professional Fees Accrued Current
ProfessionalFeesAccruedCurrent
60276
CY2023Q4 myo Professional Fees Accrued Current
ProfessionalFeesAccruedCurrent
52202
CY2024Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
160104
CY2023Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
231108
CY2024Q2 myo Accrued Liabilities Customer Deposit
AccruedLiabilitiesCustomerDeposit
1595300
CY2023Q4 myo Accrued Liabilities Customer Deposit
AccruedLiabilitiesCustomerDeposit
1114979
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
158458
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
354083
CY2024Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
5868407
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
4885944
CY2023Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
13169074
CY2023Q1 myo Salesofprefundedwarrants
Salesofprefundedwarrants
6830926
CY2023Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.325
CY2023Q1 myo Per Sale Price Of Warrants
PerSalePriceOfWarrants
0.3249
CY2023Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
5700000
CY2023Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.0001
CY2023Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
5413334
CY2023Q3 myo Salesofprefundedwarrants
Salesofprefundedwarrants
1920000
CY2023Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.6
CY2023Q3 myo Per Sale Price Of Warrants
PerSalePriceOfWarrants
0.5999
CY2023Q3 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
3900000
CY2023Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.0001
CY2024Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1354218
CY2024Q1 myo Salesofprefundedwarrants
Salesofprefundedwarrants
224730
CY2024Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
3.8
CY2024Q1 myo Per Sale Price Of Warrants
PerSalePriceOfWarrants
3.7999
CY2024Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
5400000
CY2024Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.0001
CY2024Q2 myo Common Stock Equivalents Pre Funded Warrants
CommonStockEquivalentsPreFundedWarrants
7721519
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
774730
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
937345
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
169499
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
172320
us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
0
CY2024Q2 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
0
CY2023Q2 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
16744
us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
16744
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-91893
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
280061
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
228395
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
451088
CY2023Q4 us-gaap Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
55000
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company has a non-cancelable sublease agreement for its corporate headquarters in Boston, Massachusetts, which expires in January 2025 and a lease agreement for office space in Fort Worth, TX. which expires in December 2025. Termination options are either not included, or have expired, for the Company’s existing operating leases. Certain arrangements have discounted rent periods or escalating rent payment provisions. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheets. We recognize rent expense on a straight-line basis over the lease term.
CY2024Q2 myo Operating Lease Right Of Use Assets
OperatingLeaseRightOfUseAssets
539500
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
289220
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
102841
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
0
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
0
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
392061
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
28123
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
363938
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
316600
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
47338
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
363938
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
87835
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
125650
us-gaap Operating Lease Cost
OperatingLeaseCost
175671
us-gaap Operating Lease Cost
OperatingLeaseCost
251299
CY2024Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1608
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
us-gaap Short Term Lease Cost
ShortTermLeaseCost
3268
us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2024Q2 us-gaap Lease Cost
LeaseCost
89443
CY2023Q2 us-gaap Lease Cost
LeaseCost
125650
us-gaap Lease Cost
LeaseCost
178939
us-gaap Lease Cost
LeaseCost
251299
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M14D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y2M12D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.233
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.233
CY2023Q4 us-gaap Program Rights Obligations
ProgramRightsObligations
142217
CY2022Q4 us-gaap Program Rights Obligations
ProgramRightsObligations
56603
CY2024Q1 myo Payments To Supplier Finance Program Obligations
PaymentsToSupplierFinanceProgramObligations
0
CY2023Q1 myo Payments To Supplier Finance Program Obligations
PaymentsToSupplierFinanceProgramObligations
128692
CY2024Q1 myo Expensed To Supplier Finance Program Obligations
ExpensedToSupplierFinanceProgramObligations
-80109
CY2023Q1 myo Expensed To Supplier Finance Program Obligations
ExpensedToSupplierFinanceProgramObligations
-132988
CY2024Q1 us-gaap Program Rights Obligations
ProgramRightsObligations
62108
CY2023Q1 us-gaap Program Rights Obligations
ProgramRightsObligations
52307
CY2024Q2 myo Payments To Supplier Finance Program Obligations
PaymentsToSupplierFinanceProgramObligations
349909
CY2023Q2 myo Payments To Supplier Finance Program Obligations
PaymentsToSupplierFinanceProgramObligations
375824
CY2024Q2 myo Expensed To Supplier Finance Program Obligations
ExpensedToSupplierFinanceProgramObligations
-78593
CY2023Q2 myo Expensed To Supplier Finance Program Obligations
ExpensedToSupplierFinanceProgramObligations
-155076
CY2024Q2 us-gaap Program Rights Obligations
ProgramRightsObligations
333424
CY2023Q2 us-gaap Program Rights Obligations
ProgramRightsObligations
273055

Files In Submission

Name View Source Status
0000950170-24-091839-index-headers.html Edgar Link pending
0000950170-24-091839-index.html Edgar Link pending
0000950170-24-091839.txt Edgar Link pending
0000950170-24-091839-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
myo-20240630.htm Edgar Link pending
myo-20240630.xsd Edgar Link pending
myo-ex31_1.htm Edgar Link pending
myo-ex31_2.htm Edgar Link pending
myo-ex32_1.htm Edgar Link pending
myo-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
myo-20240630_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending